Uterine fibroids are benign hormone-sensitive tumors of uterine smooth muscle cells leading to heavy menstrual bleeding and pelvic pain. Ulipristal acetate (UPA) is an emerging medical treatment of fibroids with the potential to be used for long-term treatment. In this context, the present article summarizes UPA’s main clinical pharmacology and pharmacokinetic (PK) properties. Ulipristal acetate has good oral bioavailability and a half-life allowing one single oral administration per day for the management of fibroids. As a steroid, UPA is a substrate for cytochrome P450 (CYP) 3A4 but does not act as an inducer or inhibitor of the CYP system or transporter proteins. With the exception of drugs modulating CYP3A4 activity, risks of drug–drug interactions with UPA are unlikely. In conclusion, besides its pharmacodynamic characteristics, UPA shows favorable PK properties that contribute to a good efficacy–safety ratio for the long-term management of uterine fibroids in clinical practice.
StewartEA. Uterine fibroids and evidence-based medicine--not an oxymoron. N Engl J Med. 2012;366
(5):471–473.
3.
ZapataLBWhitemanMKTepperNKJamiesonDJMarchbanksPACurtisKM. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010;82
(1):41–55.
4.
DonnezJSchrursBGillerotSSandowJClerckxF. Treatment of uterine fibroids with implants of gonadotropin-releasing hormone agonist: assessment by hysterography. Fertil Steril. 1989;51
(6):947–950.
Watson Laboratories Inc. Watson Laboratories study UL1102: An Open-Label, Crossover Study to Investigate the Effects of Multiple Doses of Ketoconazole on the Pharmacokinetics of a Single Dose of Ulipristal Acetate in Healthy Female Subjects. Study Report2011.
12.
PohlOOsterlohIGottelandJP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. J Clin Pharm Ther. 2013;38
(6):512–517.
13.
PohlOOsterlohIGottelandJP. Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day. J Clin Pharm Ther. 2013;38
(4):314–320.
14.
PregLemSA.PregLem study PGL12-011: Quantitative Predicition of Systemic Exposure to PGL4001 (Ulipristal Acetate) and the Effects of Concomitant CYP3A4 Inhibitors/Inducers Using Prior in Vitro and in Vivo Data. Study Report2012.
15.
PregLemS.A.PregLem study PGL12-010: Assessment of Potential Substrate and Inhibitor of PGL4001 of Efflux (BCRP and BSEP) and Uptake (OCT1, OCT2, OAT1, OAT3, OATP1B1 and OATP1B3) Transporter. Study Report2012.
16.
PregLemS.A.PregLem study PGL09-007: P-gp Interaction Studies of Ulipristal Acetate and PGL4002 in Caco-2 Cell Monolayer System. Study Report2009.
17.
Watson Laboratories Inc. Watson Laboratories study UL1105: An Open-Label, Crossover Study to Assess the Effects of 10 mg Ulipristal Acetate on the Pharmacokinetics of Fexofenadine (Allegra) in Healthy Female Subjects. Study Report2012.
18.
WallachEEVlahosNF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104
(2):393–406.
19.
HarjuE. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet. 1989;17
(2):69–89.
20.
CampbellNRHasinoffBB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol. 1991;31
(3):251–255.
21.
Watson Laboratories Inc. Watson Laboratories study UL1103: An Open-Label, Crossover Study to Investigate the Effects of Oral Iron Administration on the Pharmacokinetics of a Single 10 mg Dose of Ulipristal Acetate in Healthy Female Subjects. Study Report2012.
22.
Watson Laboratories Inc. Watson Laboratories study UL1101: An Open-Label, Crossover, Comparative Bioavailability Study of 10 mg Ulipristal Acetate After a High-Fat Meal or Under Fasting Conditions. Study Report2011.
23.
PohlOOsterlohILecomteVGottelandJP. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013;51(1):26–33.
24.
DonnezJTatarchukTFBouchardP. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366
(5):409–420.
25.
DonnezJTomaszewskiJVazquezF. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366
(5):421–432.
26.
Watson Laboratories Inc. Watson Laboratories study UL1106: An Open-Label, Prospective Study to Evaluate the Pharmacokinetics and Safety of a Single Oral 10 mg Dose of Ulipristal Acetate in Female Subjects with Moderately Impaired Hepatic Function Compared to Healthy Matched Subjects with Normal Hepatic Function. Study Report2012.
27.
JangGRBenetLZ. Cytochrome P4503A4-mediated N-demethylation of the antiprogestins lilopristone and onapristone. Drug Metab Dispos. 1997;25
(10):1119–1122.
28.
KhanKKHeYQCorreiaMAHalpertJR. Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metab Dispos. 2002;30
(9):985–990.
29.
ZurthCKagelsF. Determination of onapristone and its N-desmethyl metabolite in human plasma or serum by high-performance liquid chromatography. J Chromatogr. 1990;532
(1):115–123.
30.
AttardiBJBurgensonJHildSAReelJR. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004;88(3):277–288.
MelisGBPirasBMarottoMF. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin Drug Metab Toxicol. 2012;8
(7):901–908.
33.
BlitheDLNiemanLKBlyeRPStrattonPPassaroM. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003;68
(10-13):1013–1017.
34.
PassaroMDPiquionJMullenN. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod. 2003;18
(9):1820–1827.
35.
Chabbert-BuffetNPintiaux-KairisABouchardP. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007;92
(9):3582–3589.
